fbpx JLABS Company News | JLABS

News


IBD Stress Test

IBD Stress Test QuickFire Challenge
Challenge ended

Up to $50,000 in grants + Access to mentorship

Consumer Health
Digital Health

The University of Oxford

 

The Translational Gastroenterology Unit (TGU) at the University of Oxford aims to blend basic science with clinical studies to improve care, find the cause, and develop a cure for diseases of the GI tract. Their work aims to define better markers that predict how patients respond to treatments for inflammatory bowel disease. They leverage IBD genetics studies performed in the UK as well as the community of researchers studying genetic risks for ulcerative colitis to perform large association studies followed by functional analyses to assess how best to use virology data.

Overview

IBD Stress Test QuickFire Challenge

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is characterized by chronic inflammation of the digestive tract. Symptoms can include severe abdominal pain, diarrhea, fatigue, and weight loss. IBD affects over 1.6 million people in the USA according to the Crohn’s and Colitis Foundation of America, and according to the National Reviews Gastroenterol & Hepatology, there are currently 2.5 million sufferers in Europe and rising incidences in newly industrialized countries in Africa, Asia, and South America. Diagnosis is challenging and often delayed, leading many patients to progress to advanced stages of the disease, requiring surgery. Increasing evidence indicates that genetic and microbial factors, combined with environmental and lifestyle factors including infections, antibiotics, and diet, likely impact the development of IBD.

What if we could better diagnose, treat, and prevent IBD by using modern technology to evaluate an individual’s state of immune and gastrointestinal health?

There is a growing hypothesis that health and disease are characterized by a person’s ability to adapt to a diverse collection of stimuli or “stressors”. Therefore, it might be possible to predict one’s risk of disease by evaluating responses to stressors. Assessing an individual’s response to stressors could reveal early signs of disease that would not be identifiable while an individual is at rest. Examples include the cardiac stress test, which measures the heart’s response to external stress induced by exercise to diagnose heart disease, and the glucose tolerance test, which measures the body’s ability to process sugar after ingesting a glucose solution to diagnose gestational diabetes. Eventually we may be able to optimize health by routinely measuring responses to stressors and stimuli that people experience on an everyday basis!

The goal of this QuickFire Challenge is to evaluate immune and gastrointestinal health and ultimately predict risk of IBD by assessing the response of the immune and gastrointestinal systems to challenges with stressors. If you have an idea for a product, technology, or methodology to investigate the response of the human immune and gastrointestinal systems to stressors, Janssen Research & Development is awarding up to $50,000 with possible mentorship opportunities to help make that idea a reality.

Criteria

Please note: These are preferred and not required criteria.

Proposals containing the following criteria are preferred, but are not required. Please keep in mind that no idea is too big or too early for consideration. Applications that clearly describe a concept or path forward to achieve these goals will also be considered during evaluation. 

Products, technologies, and methodologies evaluated in-human or using human samples (e.g., ex vivo) are preferred. However, in vivo, in vitro, or other types of model systems are also encouraged. Proposals that demonstrate proof-of-concept are preferred. For example, proposals demonstrating that the response to stressors correlates with specific phenotypes, can differentiate between varying states of health, or can predict risk of disease.

Examples

Please note that the following are meant to represent examples only. If you have an idea that falls outside of these examples, we strongly encourage you to apply!

Stressors/Stimuli

Examples of stressors or stimuli that may be evaluated include but are not limited to:

  • Dietary Factors: There is increasing evidence that diet might contribute to the development of IBD. Proposals for evaluating the ability of the human immune and gastrointestinal systems to adapt upon challenge with dietary stimuli are sought.
  • Infection or Microbial Factors: Evidence suggests that viral or bacterial infections and exposure to microbial stimuli might represent triggers for IBD. Proposals for evaluating the ability of the human immune and gastrointestinal systems to adapt upon challenge with infection or microbial stimuli are sought.
  • Other Environmental or Lifestyle Factors: Proposals for evaluating the response of the human immune and gastrointestinal systems to other types of stressors, for example, specific environmental or lifestyle stimuli associated with IBD, are also strongly encouraged.

Responses to Stressors/Stimuli

Examples of responses to stressors or stimuli that may be evaluated include but are not limited to:

  • Measures of intestinal permeability and gut barrier health
  • Innate immune system function, including trained immunity
  • Measures of immune tolerance, including oral tolerance
  • Cellular stress responses
  • T-cell exhaustion

Proposals for evaluating other types of responses relevant to IBD are highly encouraged.

Why this challenge matters

 

A significant need exists to accurately predict who is at high risk of developing IBD so that safe interventions can be provided to prevent progression to clinical disease. Janssen Research & Development and Johnson & Johnson Innovation have a successful history in creating new markets, delivering breakthrough innovation and establishing strong partnerships built on a shared vision. We believe a good idea can come from anywhere, and it’s our goal to break through the noise of the crowded landscape and to accelerate the development of novel technologies, treatments, and pharmaceuticals to provide solutions to patients.

Application Process

 

Proposals should include: (1) definition of the stressor(s) to be applied; (2) definition of the human population or model system used to evaluate the response to the stressor; and (3) definition of how the response will be measured.

The goal of this QuickFire Challenge is to employ response to stressors in order to evaluate immune and gastrointestinal health and to ultimately predict risk of IBD. Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
• Potential to impact healthcare outcomes in a strategic area of interest
• Uniqueness of solution & level of competition in current market
• Quality & feasibility of technology
• Team credibility & capabilities
• Clarity of plan: Milestones & defined go/no go decisions

America/New_York
Applications Open
America/New_York
Applications Deadline
America/New_York
Judging Commences
November 2018
Winners Announced

Reward

Up to $50,000
  • Up to $50,000 in grants
  • Access to a network of Johnson & Johnson Innovation experts

Submit your idea today!


Don’t miss the deadline

 

About Janssen Pharmaceutical, Companies of Johnson & Johnson

At the Janssen Pharmaceutical, Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.

We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at @JanssenGlobal.

 

 


About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation, JLABS (JLABS), Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto. New JLABS in NYC and Shanghai have been announced, and in February 2018, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe.  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

Other news

Want to know more about the JLABS Portfolio?

By JLABS

Read full story

Lung Cancer Innovation QuickFire Challenge

Jlab_Quickfire-2018-06-12
lung cancer
Challenge ended

$750,000 (¥4.7M) in Grants + Residency + Mentoring

Surgical Oncology
Therapeutics

                        点击这里阅读中文

Awardees

Lung%20Cancer%20Innovation%20QFC%20Awardees.png

 

DNX Biopharmaceuticals

 

DNX Bio is a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases. Founded in 2014 and headquartered in Irvine, CA, USA, DNX is pursuing the development of new therapeutic proteins utilizing a 21st century, half-life extension platform technology known as PASylation, which is in-licensed from XL-protein GmbH. XLp has granted DNX a worldwide exclusive license under its patents and know-how related to the PASylation technology to develop and commercialize several PASylated products.

 

Hawkeye Bio

 

Hawkeye Bio was launched in 2018 in California to commercialize novel, clinically validated breath analytics for the detection of lung cancer. Lung cancer is the leading cause of cancer deaths among both men and women[1]. Lung cancer often has no symptoms until it has metastasized, because there are few specialized nerves (pain receptors) in the lungs. Lung cancer is diagnosed late 84% of the time, when treatment options are more limited. Despite progress in biomarker discovery and targeted therapy, lung cancer mortality remains unacceptably high worldwide. Hawkeye’s mission is lung cancer interception to bring about a solution to this problem.

 

NE Scientific

 

NE Scientific is a Boston-based startup company developing a surgical guidance software for supporting physicians in targeting tissues during the percutaneous ablation of liver and lung tumors. The Accublate (TM) guidance software simulates in real-time the physics taking place during the ablation and determines the ablation volume in a patient-specific way. This information is generated intraoperatively and overlaid to CT images of the patient, helping the physician in achieving a complete treatment of all malignant tissues.

[1]HawkeyeBio.com, 2019

The Challenge

Image Paragraph

The average person breathes in 432 liters of oxygen every single day, a vital component in sustaining the trillions of cells in the body. Humans can survive just a few minutes without oxygen.  To that end, it is essential that we protect our lungs.  

Is there a way to cleanse the lungs after exposure to carcinogens much like a toothbrush cleanses the mouth after eating? Is there a way to shield the lungs from carcinogens much like sunscreen shields us from damaging UV exposure?  These are a few of the provocative ideas Johnson & Johnson Innovation hopes to trigger through the Lung Cancer Innovation QuickFire Challenge. 

Lung cancer is a major cause of global morbidity and mortality with approximately 1.6 million deaths globally each year.  Unlike other diseases, lung cancer is caused by prolonged environmental exposure to carcinogens that overwhelm a human’s natural defenses and result in inflammation, genomic changes and ultimately tumor growth.  Although a global epidemic, it is unclear what makes one individual over another more susceptible to developing lung cancer.  

Johnson & Johnson (China) Investment Ltd. and Johnson & Johnson Innovation LLC are committed to prioritizing lung health.  How do we leverage the totality of science and technology to achieve comprehensive lung health -  to ultimately prevent, intercept and cure lung cancer?

Up to three innovators with the best ideas, technologies, or solutions that improves human healthcare related to preventing, intercepting or curing lung cancer will be awarded up to a total of $750,000 in grants, a voucher for one year of residency at JLABS @ Shanghai (optional), including a laboratory bench, workstation and access to the JLABS community, and mentorship from Johnson & Johnson Innovation and/or its affiliates.

Reward

Up to $750,000 (¥4,775,850) in total grants 
  • 1 year residency at JLABS @ Shanghai (Optional)
  • Mentoring & coaching from experts from Johnson & Johnson Innovation and/or its affiliates

Areas of Interest

We encourage applications from innovators working on all aspects of lung health, including solutions focused on Lung Cancer:

  • Prevention: Approaches to identify risks and for warding off onset of lung cancer
  • Interception: Arrest lung cancer as it develops, prior to clinical onset
  • Cures: Completely eliminate presence of lung cancer and reverse damage to restore full health

Please keep in mind that no idea is too big or too early for consideration. Applications that clearly describe a concept or path forward to achieve these goals will also be considered during evaluation.  

We are interested in applications addressing the full spectrum of lung health. Specific areas of interest include, but are not limited to: 

  • To develop approaches to reduce, prevent, or protect from exposure to respiratory carcinogen, including novel approaches to smoking cessation 
  • To develop approaches to measure the exposure to and biological effect from respiratory carcinogens
  • To develop diagnostics/biomarkers to detect pre-cancers or early-stage malignant lesions
  • To develop approaches, including surgical, medical, behavioral, digital or others, to prevent or intercept lung carcinogenesis
  • To discover new tools for diagnosis and extirpation of curable lung cancers
  • To develop new treatments or treatment modalities for the cure of lung cancer

Approaches should include the following areas:

  • Pharmaceuticals
  • Consumer products
  • Medical devices
  • Global public health
  • Health technologies
  • Cross-sector initiatives – an integration of one or more the aforementioned areas of focus 

Application Process

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)

Timeline

June 14, 2018 (China Time)
Applications Open
September 21, 2018 (China Time)
Submission Deadline
Spring 2019
Winner Announcement at JLABS @ Shanghai Launch

Apply Now


Don’t miss the deadline

Why this challenge matters to us

We believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health.

FAQs

 

Q: What if I’m having trouble accessing the portal/website?

A: Make sure your browser is up to date and accepting cookies. You can contact customer service at [email protected] if you are having technical difficulties as well.

 

Q: Is residency at JLABS @ Shanghai required?

A: No. Residency is encouraged but optional.

 

Q: Do I need to reside in Shanghai or a Chinese entity in order to apply?

A: No. We are seeking innovations globally.

 

Q: For prizes involving residency at JLABS, what does that entail and for how many people?

A: For challenges involving residency at JLABS, that entails 1 lab bench and 1 workstation (desk) for 2 people maximum. If you have more employees, additional footprint can be rented.

 

Q: For prizes involving residency at JLABS, are there any expenses not covered by JLABS?

A: Each applicant will be required to submit to a background check, which is subject to a minimal fee.  We also collect a deposit that is refundable at the end of the lease term. There may be other expenses, but this will be dependent on the work that the company is doing in JLABS.  There may also be fees associated with EH&S waste, specialty equipment, printing and phone calls.

 

Q: Will JLABS pay for my living costs, relocation or visas?

A: No, any additional fees and paperwork are up to the winner.

 

Q: Can I submit supporting documents (for example a video) as part of my application? 

A: You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

 

Q: Is it ok if some of the information I submit is confidential?

A: Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.

 

Q: What happens with IP (Intellectual Property)?

A: As this is a no strings attached arrangement, JLABS does not acquire any IP.  Any IP creation and/or protection remains the sole responsibility of the inventors.

 

Q: Is a patent required to apply?

A: No, a patent is not required to apply.  However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.

 

Q: What kind of science / technology is appropriate for the Challenges? 

A: We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering

 

Q: Who is eligible to apply?

A: Each Challenge has its own terms & conditions that can be found prior to filling out the application.

 

Q: What are the specific criteria for application?

A:  Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)

 

Q: Who can I contact if I have questions about the Challenges or the application process?

A: Please contact [email protected] with any questions.

 

Q: Where do I apply? And do I have to complete the application in one sitting?

A: Apply at https://jlabs.jnjinnovation.com/form/lung-qfc-apply. You are able to save your work and log back in to finish at a later time if needed.

About Johnson and Johnson Innovation, JLABS

Picture1.png

 

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto. New JLABS in NYC and Shanghai have been announced, and in February 2018, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe.  For more information about JLABS, please visit jlabs.jnjinnovation.com.

About Johnson & Johnson (China) Investment Ltd

Picture1_0.png

 

 

 

 

强生公司

强生是全球业务分布广泛、综合性的跨国医疗保健企业,业务涉及消费品、制药、医疗器材三大领域,1985年在华创立了第一家合资企业。强生遵循企业信条的价值观,致力于践行“关爱全世界,关注每个人”的健康愿景,以领先的科技研发创造创新的理念、产品和服务,为改善人类健康和福祉而不懈努力。每天,强生遍布世界各地的员工,与他们的合作方一起,为全球消费者和病患带来更健康、更快乐、更长寿的生活。

 

 


 

JLABS @ TMC QuickFire Challenge

JLABS @ TMC QuickFire Challenge
Challenge ended

Residency at JLABS

Consumer Health
Therapeutics

Winners

Image paragraph

Developing next-generation surgical adhesives based on polyurethane, which permit quick and safe wound closure, topically as well as inside the human body.

Image paragraph

Aortix is a heart pump implanted without surgery, designed from the ground-up as a safe and effective treatment for chronic heart failure which affects one in five adults in the United States.

Image paragraph

High-throughput antibody discovery platform for breast and other cancers focused on identifying therapeutics targeted at novel antigens induced by the tumor microenvironment. 

Alterna Therapeutics, Inc.

Developing new therapeutics to treat diabetes and obesity.

The Challenge

In honor of the upcoming Grand Opening of JLABS @ TMC, Johnson & Johnson Innovation has launched a QuickFire Challenge to award new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ TMC community for one year.

Latin America QuickFire Challenge

Latin America QuickFire Challenge
Challenge ended

Residency at JLABS

Therapeutics

Winners

Image paragraph

Focused on the production of recombinant proteins from the Zika virus capsid that could be used for isolating or developing anti-Zika monoclonal antibodies, which may be used to treat or reduce the viral load of infected individuals.

The Challenge

As part of the innovation forum for Latin America, Johnson & Johnson Innovation has committed to award one new game-changing early-stage innovation company from Latin America access to the Johnson & Johnson Innovation, JLABS community for six months through participation in a QuickFire Challenge. The JLABS QuickFire Challenge for Latin America is to support ideas to trigger health innovation from the Latin America region.

JLABS @ Toronto QuickFire Challenge

JLABS @ Toronto QuickFire Challenge
Challenge ended

Residency at JLABS

Consumer Health
Digital Health
Therapeutics

Winners

Image paragraph

A4i is a digital health innovation company that provides clinically-proven mobile interventions to significantly enhance treatment engagement and quality of life for individuals with psychosis and other major mental health challenges.

Image paragraph

An innovative gene therapy company focused on immune-oncology and rare diseases.

Image paragraph

Developing novel therapeutics for metastatic cancers employing a comprehensive approach to reverse the metastatic state of tumor cells.

Image paragraph

Achieving high-precision personalized cancer therapy with multimodal nano imaging agents: lead application in image-guided surgery”.

Image paragraph

Creators of a seizure tracking tool that uses devices patients already own and wear. 

Image paragraph

Regular molds have one shape; PinPress is a shape-shifting tool that gives you a thousand molds in one.

Image paragraph

Helping people enjoy the sun with a smart indicator of ultraviolet light that changes colour to warn people of their sun exposure.

The Challenge

In honor of the upcoming Grand Opening of JLABS @ Toronto, Johnson & Johnson Innovation has launched a QuickFire Challenge to award new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ Toronto community for one year. In addition, all winners will receive memberships from BIOTECANADA and OBIO , and the Medical Device winner will receive a membership from Medec.

JLABS @ LabCentral QuickFire Challenge

JLABS @ LabCentral QuickFire Challenge
Challenge ended

Residency at JLABS

Consumer Health
Digital Health

Winners

Image paragraph

Cyteir Therapeutics is developing new drugs to treat cancer and chronic autoimmunity.

Image paragraph

Riparian Pharmaceuticals is an early-stage biotechnology company employing innovative models of vascular pathophysiology to discover novel therapeutics.

Image paragraph

XTuit Pharmaceuticals is pursuing novel approaches to improving cancer therapy by targeting the tumor microenvironment.

The Challenge

In honor of the upcoming Grand Opening of JLABS @ LabCentral, Johnson & Johnson Innovation has launched a QuickFire Challenge to award new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ LabCentral community for one year.

World Without Disease QuickFire Challenge

World Without Disease QuickFire Challenge
World Without Disease QuickFire Challenge
Challenge ended

$ 500,000 + Optional residency at JLABS

Consumer Health
Therapeutics

Winners

Image paragraph

Maryland-based Glyscend, Inc., led by Ashish Nimgaonkar, M.D., Co-founder and CEO, is developing transformative therapies for metabolic diseases (such as type 2 diabetes and obesity) by reducing the concept of bariatric (gastric bypass) surgery into a pill. While type 2 diabetes has traditionally been treated with oral and injectable drugs, these therapies compound over a patient’s lifetime causing weight gain and potentially leading to greater insulin resistance. Bariatric surgery has been shown to have a profound beneficial effect, not only on obesity but also on type 2 diabetes independent of weight loss. Based on the insights from these surgeries, Glyscend is developing the first orally administered intestinal barrier which mimics the intestinal bypass portion of bariatric surgery, thus providing the therapeutic benefits of this surgery in a pill form.

Image paragraph

California-based Neurotrack, led by Elli Kaplan, CEO, is on a mission to transform the diagnosis and prevention of memory loss and related diseases like Alzheimer’s. The company’s product is the Imprint™ Check-Up, a five-minute test that uses eye-tracking technology to assess cognitive decline before symptoms appear. The early diagnosis of memory loss is critical for prevention of cognitive decline and this test is the only tool that can predict memory loss before it starts. In addition, Neurotrack offers a Cognitive Health Program that provides users with tools and advice to make lifestyle changes scientifically proven to reduce the risk of cognitive decline and diseases like Alzheimer’s.

Read More

Read about how innovators are transforming the way illnesses are treated in the most forward-thinking way possible through this challenge: here

Image paragraph

RMIT University’s Micro/Nanomedical Research Center, led by Leslie Yeo, Ph.D., has developed core technology consisting of a portable handheld personalized nebulization platform that enables the aerosolization of drugs for their delivery via inhalation to the lungs. The technology not only offers needle-free administration and the opportunity for systemic delivery of both small and large molecule therapeutics, but also the opportunity for local targeting directly to the lungs, which makes it very attractive for targeting lung diseases, including lung cancer, which is the specific area that represents a critical unmet medical need.

The Challenge

At Johnson & Johnson Innovation and Janssen Research & Development, our goal is to improve the health and wellness of people around the world. To that end, we have a passionate and engaged workforce across our consumer, medical device and pharmaceutical units who are interested in finding and deploying comprehensive, end to end, integrated solutions which take into account the world in which we live today. Johnson & Johnson Innovation and Janssen Research & Development are bringing together the consumer, medical device and pharmaceutical sectors to award $1.5M to the person or team(s) who submits the best idea, technology, or solution that will address a critical health need for the world's population.

Advancing the Safe Use of Healthcare Products QuickFire Challenge

Advancing the Safe Use of Healthcare Products QuickFire Challenge
Advancing the Safe Use of Healthcare Products QuickFire Challenge
Challenge ended

Up to $200,000 USD*

Consumer Health
Digital Health
Surgery

Winner

Image paragraph

CertaDoseTM offers a unique measuring system that helps eliminate dosing errors in kids by using any of the industry standard methods of estimating a patient’s weight, including length and age, and automatically converts that weight to the appropriate dosage on our color-coded syringe.  CertaDoseTM is an FDA-cleared syringe clinically proven to reduce critical dosing errors to zero. Each syringe is labeled with easy to recognize color zones that match the Broselow® color system to help clinicians verify the correct dose during critical, time-sensitive situations.

The Challenge

Image paragraph

At the Johnson & Johnson Office of the Chief Medical Officer (OCMO) we strive to enable healthcare practitioners, physicians, surgeons, patients and consumers to use our products safely by providing the most complete information and the best education and training we can.

To that end, Johnson & Johnson Innovation and the OCMO are looking to reward up to $200,000 in multiple grants, and one year of JLABS space, to the individuals or teams who submit the best ideas on how to educate, inform and provide clarity around healthcare product safety.

Rewards and benefits

Up to $200,000 USD*
  • *in grants for multiple winners
  • Entrance to an available JLABS
  • Mentoring & Coaching

QuickFire Challenge innovation focus areas

Empowering patients and consumers to make more informed healthcare decisions by providing better information and education about the safety of healthcare products (pharmaceuticals, medical devices and consumer products).

This challenge focus area seeks ways to maximize consumer and patient education and understanding of healthcare products and their safety and efficacy, including medical devices, pharmaceuticals and consumer products.

The objective is to empower patients, consumers and healthcare providers to make more informed decisions and obtain maximum benefit from product use through greater understanding of safety data and by ensuring more effective communication and enhancing education.

Image paragraph

Improving training and development for surgeons by identifying new models that simulate the operating room environment.

This focus area seeks new and robust models and methods to evaluate medical devices used by surgeons in a simulated environment representative of operating room procedures, with the goal of helping the surgeon understand how to safely and effectively use a medical device and understand variability in device and performance/outcome.

Entries should focus on soft tissue models that anatomically represent organ-specific anatomic features and biological properties, such as tissue injury, bleeding and clotting responses.

Image paragraph

Empowering patients and consumers to more safely administer and handle healthcare products.

The third focus area seeks ways to address the challenge of prescription medication errors. Entries should identify patient- and consumer-focused devices, solutions or platforms that will prevent errors and solutions to promote safe storage and administration or extend the shelf life of prescription, over-the-counter or cosmetic products.

Image paragraph

Timeline

CST
Applications Open
CST
Submission Deadline
CST
Winner Announced

Why this challenge matters to us

True benefit from healthcare products requires an unrelenting focus on patient- and consumer-centered safety, a principle that is at the heart of Johnson & Johnson’s Credo and is embodied in the mission of the Office of the Chief Medical Officer (OCMO).  Working to ensure that J&J is developing and making available the safest products possible is what the nearly 1000 employees of OCMO work towards each day.  Always looking for better ways to address safety on behalf of patients and consumers, we are embarking on a Quickfire Challenge to identify new and innovative ideas to increase the safe use of our products.

Application process

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential to impact healthcare outcomes / move the needle on medical safety
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Clarity of plan: Milestones & defined go/no go decisions

Deadline to apply is May 24, 2017
Winner(s) will be announced in November

About Johnson & Johnson Office of the Chief Medical Officer

Established in 2013, the Johnson & Johnson Office of the Chief Medical Officer (OCMO) is accountable for bringing scientific excellence, bioethics- and values-driven decision-making, as well as a commitment to transparency and medical safety assessments that are independent of commercial interests, to the many efforts that keep patients and consumers at the heart of everything we do. The OCMO has oversight across Johnson & Johnson for medical safety, epidemiology, R&D operations and creating and maintaining global bioethical policies.

 

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation – JLINX, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

 

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

Image paragraph
Image paragraph

You can find our press release here.

Seoul Innovation QuickFire Challenge

Seoul Innovation QuickFire Challenge
Challenge ended

KRW 150,000,000*

Digital Health
Therapeutics

Winners

Image paragraph

GPOWER Inc. is an IoT skincare company providing hardware and software solutions to help monitor, manage and improve skin health.

Company website : www.mybarrierskin.com

Image paragraph

Nu Eyne is a medical device company that focuses on treating ophthalmological disorders, such as dry eye syndrome and eye pain, by applying neuromodulation and tissue engineering.

Company website: www.nueyne.com

The Challenge

Image paragraph

Johnson & Johnson Innovation, JLABS (JLABS) in collaboration with Seoul Metropolitan Government (SMG), Korea Health Industry Development Institute (KHIDI),  Janssen Korea Ltd. and Johnson & Johnson Medical Korea Ltd. have launched the Seoul Innovation QuickFire Challenge to attract global game-changing, early stage innovations. Two winners with the best idea, technology, or solution that will address a health need for the world's population will be a receipt of up to KRW 150,000,000 (approximately US$134,000) in grant funding, entrance to the Seoul Bio Hub (each winner will receive KRW 70,000,000 cash award and a space voucher for KRW 5,000,000 which may be used toward the rent and utilities at the Seoul Bio Hub), and a year of mentorship and coaching.

Rewards and benefits

KRW 150,000,000*
  • *in funding for up to two winners
  • Entrance to the Seoul Bio Hub
  • (*each winner will receive KRW 70,000,000 cash award and a space voucher for KRW 5,000,000 which may be used toward the rent and utilities at the Seoul Bio Hub)
  • A year of mentorship and coaching from Johnson & Johnson Innovation and KHIDI

Areas of interest

This global competition will award the person or team(s) who submits the best idea, technology, or solution focused in the following areas:

  • Health technologies
  • Medical devices
  • Therapeutics

In the following sectors:

  • Bone & join disease
  • Cardiovascular and metabolic disease
  • Immunology
  • Infectious disease
  • Neuroscience
  • Oncology

Why this challenge matters to us

At Johnson & Johnson Innovation, we believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health. Seoul, Korea has a robust healthcare innovation ecosystem and Johnson & Johnson is excited to be a part of it through this QuickFire Challenge.

Frequently Asked Questions

What is being awarded and to how many innovators/companies?

Up to two winners will be awarded a combined KRW 150,000,000 & entrance to the Seoul Bio Hub. Each winner will receive KRW 70,000,000 cash award and a space voucher for KRW 5,000,000 which may be used toward the rent and utilities at the Seoul Bio Hub.

Where do I apply?

You can apply through https://jnjawards.fluidreview.com/

Who is eligible to apply?

We encourage applications from everyone interested in the Seoul Innovation QuickFire Challenge from across the globe; however, per the terms and conditions, not all applicants may be eligible to win the Seoul Innovation QuickFire Challenge.

Applicants may be individuals, entrepreneurs, academics, biotech researchers or an early-stage company that is less than 60 months old.

Applicant must not be in default of payment of dues owed to any financial institutions and/or default in payment of any national and/or local taxes in South Korea.

While all potential applicants are encouraged to apply, those that are Health Care Providers (“HCPs”), Government Officials (“GOs”) (see definitions below), which for purposes here include any individual who is a “public official” as defined under the Act on Prohibition of Improper Requests and Provision/Receipt of Money or Valuables, or any organization affiliated with either, will be subjected to additional review, and may not be ultimately eligible to continue with the application and selection process.

Definitions:

Government Official or “GO” means any official or employee of a government agency or instrumentality of the government including but is not limited to a political party, party official or candidate, or public international organizations. It also includes individuals representing himself or herself as a GO, for example, a customs official, inspector, auditor, investigator, elected official, or employee of a government ministry or agency.  Note that this definition includes agents or employees of some non-governmental (NGO) organizations where those organizations perform quasi-governmental services such as distribution of drugs and medical devices or delivery of health care services, an individual who is an agent or consultant to a government agency, or provides a primary business address at a government facility, uses a military title  or rank, supplies an email address associated with a government entity or is otherwise known or believed to be a government employee. Health Ministries and government-owned hospitals often employ HCPs who may be GOs under local law. A private HCP that provides consulting services or otherwise acts as an agent of the government, these individuals should be considered Government Officials. It includes any individual who is a “public official” as defined under the Act on Prohibition of Improper Requests and Provision/Receipt of Money and Valuables of Korea.

“Health Care Provider” or “HCP” means:

  • All physicians; and 
  • Any other individual, institution or entity with the ability to prescribe, acquire or influence the prescription or acquisition of the Johnson & Johnson (including its affiliates and subsidiaries) products or services at issue, and either of the following: 
  • The products at issue are regulated or registered as medicinal products or devices (or their equivalents) in the applicable country; or
  • The products or services at issue are subject to reimbursement by government or third parties; or, are offered for sale with products or services subject to such reimbursement.

Examples of HCPs -- depending on the nature of the products or services at issue -- may include, but are not limited to, doctors, nurses, physician assistants, pharmacists, other para-medical staff, members of product formulary committees, health economists, key opinion leaders including scientists and/or PhD’s, clinical investigators and researchers, administrative and management employees of private and public hospitals, HCPs-in-training and medical societies.

What sectors are you looking for?

Healthcare solutions from across the globe in the following areas::

  • Health technologies
  • Medical devices
  • Therapeutics

In the following sectors:

  • Bone & join disease
  • Cardiovascular and metabolic disease
  • Immunology
  • Infectious disease
  • Neuroscience
  • Oncology
What are the specific criteria for application?

All applicants must outline their interest in Seoul, South Korea, including plans to work in Seoul and engage with the local ecosystem as well as how the mentorship can critically support their innovation. Applicants may be individuals, entrepreneurs, academics, biotech researchers or an early-stage company that is less than 60 months old and must not be in default of payment of dues owed to any financial institutions and/or default in payment of any national and/or local taxes in South Korea.

Do applicants have to reside in Korea in order to apply?

No, this is a global challenge. However, if selected as a winner or finalist, at least one core team member of the applicant company must reside in the Seoul Bio Hub for no less than 1 year (each winner will receive a space voucher for KRW 5,000,000 which may be used toward the rent and utilities at the Seoul Bio Hub).

Can I submit supporting documents (for example a video) as part of my application?

You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

Is it ok if some of the information I submit is confidential?

Do not submit confidential information. Only non-confidential information should be submitted.

*For further information on eligibility for this QuickFire Challenge, please refer to the Terms & Conditions presented in your application form.

Application process

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Clarity of plan: Milestones for the next 12 months
  • Idea submission outlines interest in the innovation ecosystem in Seoul, South Korea

Deadline to apply is September 29, 2017
Winner(s) will be announced in December.

Timeline

KST
Applications Open
KST
Submission Deadline
KST
Judging Process Begins
KST
Winners Announced at Seoul Bio Hub

About Johnson & Johnson Innovation

Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JLINX, Johnson & Johnson Innovation – JJDC and our Business Development teams to create customized deals and novel 4 collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

 

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.


JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

 

About Janssen Pharmaceutical Companies

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/korea .


About the Johnson & Johnson Medical Devices Companies

The Johnson & Johnson Medical Devices Companies’ purpose is to reach more patients and restore more lives. Having advanced patient care for more than a century, these companies represent an unparalleled breadth of products, services, programs and research and development capabilities in surgical technology, orthopaedics, cardiovascular and specialty solutions with an offering directed at delivering clinical and economic value to health care systems worldwide.

 

About Seoul Metropolitan Government (SMG)

Seoul is a global city located at the center of Northeast Asia characterized by easy access to metropolitan cities around the world and convenient living conditions, particularly with nine (9) subway lines, 6,000 bus stops, and 22 international schools.

The Seoul Metropolitan Area is an optimal location to foster technology-oriented venture firms as it houses more than 20,000 research institutes, 139 universities, and 133 general hospitals, concentrating top-caliber workforce and technology in a single location.

The Hongneung Biomedical Cluster, home to Seoul Bio Hub, which is slated to open in september 2017, houses national research institutes (KIST,etc.), research-oriented hospitals, and universities. The Seoul Metropolitan Government plans to offer facilities and equipment for the fast growth of technologically advanced startups and help businesses, researchers, and businessmen develop and commercialize innovative technologies via support in investment, administration, and information services.

 

About Korea Health Industry Development Institute (KHIDI)

KHIDI is a government-affiliated institution which performs professional and systematic support to develop domestic healthcare industry and enhance healthcare services. Since its establishment in 1999, KHIDI has led expansion of healthcare research and development investment and building competitiveness of Korea's healthcare industry, i.e., health services, pharmaceuticals, medical devices, food and beauty-cosmetic. KHIDI is designated as an operating body of Seoul Bio Hub, and plans to utilize its infrastructure and network to facilitate cooperation with relevant stakeholders. For more information, please visit http://www.khidi.or.kr/eps.

 

About Seoul Bio Hub

Seoul Bio Hub, located in northern Seoul and slated to begin operations in September 2017, is a life science innovation center sponsored by SMG and operated by KHIDI. The key function is to support early stage life science companies’ growth and commercialization by providing full-service wet laboratory and office spaces, shared equipment, networking events, training programs, and investor relation opportunities. As the only biotech startup platform located in Seoul, it leverages its geographical advantages to accelerate the startup ecosystem, by facilitating cooperative networks among research-driven hospitals, universities, national research institutes, and venture capitals within close vicinity. For more information, please visit http://www.seoulbiohub.kr.

bottom-banner-version-5.png

 

You can find our press release here.

Artificial Intelligence for Drug Discovery QuickFire Challenge

JLABS - Artificial Intelligence for Drug Discovery QuickFire Challenge
Artificial Intelligence for Drug Discovery QuickFire Challenge
Challenge ended

Up to $100,000 USD*

Immunology

Winners

 

A2A

A2A Pharmaceuticals: At A2A Pharmaceuticals, our mission is to leverage proprietary computational systems including A.I., to accelerate development of novel drug alternatives for life threatening diseases like cancer, bacterial infections and muscular dystrophy.  

 

Envisagenics

Envisagenics: Cloud-based drug-target discovery platform (SpliceCore) using AI to predict disease-causing aberrant splicing through the analysis of massive amounts of RNA-seq data. 

 

Traceryo

Tracery Ophthalmics: Tracery is a clinical stage ocular imaging and health tech company focused on Age Relate Macular Degeneration and blinding eye disease.  

The Challenge

Image paragraph

At Johnson & Johnson Innovation and Janssen Research & Development our goal is to improve the health and wellness of people around the world. Artificial intelligence (AI) poses unlimited opportunity for us to make a transformative impact on patients. Whether it be through new drug combinations, improved medical diagnostics, better accuracy in personalized medicine, or many other benefits - AI could save scientists valuable research time and bring new treatments to patients more quickly. To that end, Johnson & Johnson Innovation is looking to award up to $100,000 in grants, one year of JLABS residency & mentorship to the individuals or teams who submit the best ideas, technologies, or solutions that are using artificial intelligence to advance healthcare.

Rewards and benefits

$100,000*
  • *Up to $100,000 USD in grants for multiple winners
  • Residency at an available JLABS location
  • Mentoring & coaching from J&J experts

QuickFire Challenge innovation focus areas

We are looking for entrepreneurs & innovators with the best ideas, technologies, or solutions across all stages (ideation, pre-clinical, clinical, post-approval) that are using artificial intelligence to advance drug discovery & development in any of these areas:

  • Oncology & Immuno-oncology
  • Immunology
  • Cardiovascular & Metabolism
  • Infectious Diseases & Vaccines
  • Neuroscience
  • Pulmonary Hypertension
  • Rare Diseases
  • Pre-clinical safety studies
  • Systems pharmacology
  • Clinical trials
  • Precision Medicine
  • Chemo-informatics
  • In silico compound & safety profiling
  • Real world evidence

Timeline

EST
Applications Open
EST
Submission Deadline
EST
Judging Commences
EST
Finalists Pitch at JLABS @ Toronto and Winners are Announced 

Application process

A panel of reviewers and judges will evaluate submissions based  on their ability to meet the following criteria:

  • Scientific/Technical Excellence
  • Novelty
  • Feasibility/Practicality
  • Perceived commercialization potential
  • Clarity on milestones and deliverables
  • Quality of Team and Resources
  • Plan for use of funds


Deadline to apply is October 27th, 2017
Winner(s) will be announced in December

About the Janssen Pharmaceutical Companies

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at Twitter.com/JanssenGlobal.

 

About Johnson & Johnson Innovation

Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JLINX, Johnson & Johnson Innovation – JJDC and our Business Development teams to create customized deals and novel 4 collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.


About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

Image paragraph
Image paragraph

JLABS San Diego QuickFire Challenge

JLABS San Diego QuickFire Challenge
Challenge ended

$25,000 in grant funds

Consumer Devices
Digital Health
Global Public Health
Therapeutics

Winner

Image paragraph

Vivreon Biosciences

Vivreon Biosciences is developing a new class of small molecule therapeutics for the treatment of chronic inflammatory diseases. Candidate therapies defend healthy tissue by targeting a previously untapped inflammatory pathway – selective blockade of the calcium release-activated calcium (CRAC) channel.

People's Choice Award

Image paragraph

Snap Bio

Snap Bio leverages an integrated platform encompassing advanced synthesis and synthetic biology, including proprietary cell-free-biosynthesis (CFB) technology, along with structure-based drug design, to develop novel new chemical entities (NCE).

This unique combination of technologies is enabling structural modification of these modular scaffolds in ways that previously were not possible, thus allowing us to rapidly optimize selectivity, solubility, cell-penetration, metabolic stability, and other properties required for clinical success.

Vote for People's Choice Award

 

Each video has been prepared and submitted by the respective company named in such video. Such information is not an endorsement or referral of any company or any of the products or services of such companies by Johnson & Johnson Innovation, LLC (“JJI”) or its affiliates. JJI makes no representations or warranties, express or implied, as to the accuracy of the content in the videos. JJI assumes no liability for any errors or omissions in the videos. The information provided does not necessarily reflect the views or opinions of JJI or its affiliates.

The Challenge

Image paragraph

In honor of the 5-year anniversary of the first Johnson & Johnson Innovation JLABS site, JLABS has launched the San Diego QuickFire Challenge to attract cutting edge, early-stage innovation from around the world. The innovator with the best idea, technology, or solution that improves human healthcare will be awarded $25,000 in grant funding, a voucher for one year of residency at JLABS San Diego, including a laboratory bench, workstation and access to the JLABS community, and mentorship from Johnson & Johnson Innovation and/or its affiliates.

Rewards and benefits

  • $25,000 in grant funds
  • A voucher for one year of JLABS San Diego residency
  • Mentorship by Johnson & Johnson Innovation and/or its affiliates

QuickFire Challenge innovation focus areas

We encourage applications from companies working on all aspects of human healthcare, and have a particular interest in the following areas:

Why this challenge matters to us

At Johnson & Johnson Innovation, we believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health.

Frequently Asked Questions

What if I’m having trouble accessing the portal/website?

Make sure your browser is up to date and accepting cookies. You can contact customer service at https://jnjawards.fluidreview.com/helpdesk/contact/ if you are having technical difficulties as well.

For prizes involving space at JLABS, what does that entail and for how many people?

For challenges involving space at JLABS, that entails 1 lab bench and 1 workstation (desk) for 2 people maximum. If you have more employees, we can rent out an additional space.

For prizes involving space at JLABS, are there any expenses not covered by JLABS?

Each applicant will be required to submit to a background check, which is subject to a minimal fee.  We also collect a deposit that is refundable at the end of the lease term. There may be other expenses, but this will be dependent on the work that the company is doing in JLABS.  There may also be fees associated with EH&S waste, specialty equipment, printing and phone calls.

Will JLABS pay for my living costs, relocation or visas?

No, any additional fees and paperwork are up to the winner.

Can I submit supporting documents (for example a video) as part of my application?

You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

Is it ok if some of the information I submit is confidential?

Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.

What happens with IP (Intellectual Property)?

As this is a no strings attached arrangement, JLABS does not acquire any IP.  Any IP creation and/or protection remains the sole responsibility of the inventors.

Is a patent required to apply?

No, a patent is not required to apply.  However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.

What kind of science / technology is appropriate for the Challenges?

We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering

Who is eligible to apply?

Each Challenge has its own terms & conditions that can be found prior to filling out the application.

What are the specific criteria for application?

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Plans for utilizing JLABS space
  • Idea submission outlines interest in the innovation ecosystem in San Diego
Who can I contact if I have questions about the Challenges or the application process?

Please contact [email protected] with any questions.

Where do I apply? And do I have to complete the application in one sitting?

You can setup an account at http:// jnjawards.fluidreview.com. You are able to save your work and log back in to finish at a later time if needed.

Application Process:

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Plans for utilizing JLABS space
  • Idea submission outlines interest in the innovation ecosystem in San Diego

Timeline

PDT
Applications open
PDT
Submission deadline
PDT
Reviewers scoring period starts
PDT
Reviewers scoring period ends
PDT
Judging process begins
PDT
Finalist presentations (judging panel selects challenge winner(s))
PDT
Winner announcement

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.
 
JLABS currently has n locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center (opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.


About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, JLABS, Johnson & Johnson Innovation - JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, please visit www.jnjinnovation.com.

1.gif

Singapore QuickFire Challenge - Metabolic Disease Innovation

Singapore Quickfire Challenge
Singapore QuickFire Challenge - Metabolic Disease Innovation
Challenge ended

Up to SGD100,000

Consumer Health
Diagnostics
Digital Health
Therapeutics

Winners

Image paragraph

Nanyang Technological University (LambdaGen) envisions development of next generation personalized therapeutics using its proprietary non-viral technological advance based on λ-integrase system that allows insertion of large fragments of DNA in a discrete number of non-random insertion sites which can be used to treat a wide range of diseases where a functional copy of a large disease-causing/therapeutic gene is required.

Image paragraph

PreventAGE Health Care, led by an experienced team, is driven by the grand ambition to fundamentally improve the lives of patients with diabetes by providing biomarker-based prognostic, actionable information on their personal risk for developing specific complications (nephropathy, retinopathy, cardiovascular diseases) far in advance of any symptoms so as to preserve health and to reduce costs.

Image paragraph

Medopad is a CE-marked patient monitoring software solution that brings together modular care monitoring tools, patient vital data tracking, and real time AI analytics to provide an easy-to-use yet holistic digital health solution.

The Challenge

Image paragraph

Johnson & Johnson Innovation, JLABS (JLABS) in collaboration with Exploit Technologies Pte Ltd (ETPL) and Singapore-MIT Alliance for Research and Technology (SMART), have launched the Singapore QuickFire Challenge - Metabolic Disease Innovation to attract game-changing, early stage innovations that address this critical health concern.

Metabolic diseases such as diabetes and obesity are posing a threat to Asia Pacific like never before. Globally, over 422 million people are living with diabetes today, and about 60% of them are in Asia. The disease burden in the region continues to evolve in epidemic proportions.

Rewards and benefits

Up to SGD100,000
  • Up to SGD100,000 in potential project money for winners*
  • Access to ETPL laboratory space
  • One year of mentoring and support for winners from the Johnson & Johnson Innovation, ETPL and SMART staff
  • * At least one core team member of the applicant must reside in Singapore for no less than 50 percent of the term of the project.

Areas of interest

This global competition will award the person or team(s) who submits the best idea, technology, or solution focused on metabolic disease in the following areas:

  • Therapeutics
  • Health technologies
  • Consumer healthcare
  • Medical devices
  • Diagnostics

Why this challenge matters to us

This Challenge aims to identify and support entrepreneur, academic, and biotech researchers with innovative ideas that have the potential of making a major difference in the lives of the millions of people in Asia Pacific and around the world who suffer from metabolic diseases such as diabetes and obesity.

Frequently Asked Questions

What is being awarded and to how many innovators/companies?

Each of up to three winners will be awarded SGD100,000 for research in Singapore, access to ETPL laboratory space and one year of mentorship and coaching by Johnson & Johnson Innovation, ETPL and Singapore-MIT Alliance for Research and Technology (SMART) staff.

Where do I apply?

You can apply through https://jnjawards.fluidreview.com/

Who is eligible to apply?

We encourage applications from everyone interested in the QuickFire Challenge however, per the terms and conditions not all applicants may be eligible to win the QuickFire Challenge.

What sectors are you looking for?

Solutions addressing metabolic disease in the Asia Pacific region in the following areas:
• Therapeutics
• Medical devices
• Consumer health
• Diagnostics
• Health technologies

What are the specific criteria for application?

All applicants must outline how the award will help them reach a critical milestone with the timeframe of a single year and provide a full “time-to-market” plan for their solution. Solutions need to meet the following criteria:
• Address a metabolic disease in the Asia Pacific region
• Integrate a novel approach within the therapeutic, device, diagnostic, consumer health and/or health technologies areas
• Address part or all of the spectrum of prevention, interception and cure

Do applicants have to reside in Singapore in order to apply?

No, this is a global challenge. However, if selected as a winner or finalist, at least one core team member of the applicant company must reside in Singapore for no less than 50 percent of the term of the project.

Can I submit supporting documents (for example a video) as part of my application?

You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

Is it ok if some of the information I submit is confidential?

Do not submit confidential information. Only non-confidential information should be submitted.

*For further information on eligibility for this QuickFire Challenge, please refer to the Terms & Conditions presented in your application form.

Application process

The submitted metabolic disease solutions will be evaluated based on their ability to meet the following criteria:

  • Address a metabolic disease in the Asia Pacific region
  • Integrate a novel approach within the therapeutic, device, diagnostic, consumer health and/or health technologies areas
  • Address part or all of the spectrum of prevention, interception and cure
  • Idea submission is innovative and creative
  • Idea submission is scalable
  • Idea submission outlines how the award would help them reach a critical milestone within the timeframe of a single year and provides a full commercialization plan.

You have to sign up for an account to get started, and you will receive an email to activate your account. You will be guided through the application process which will include signing our general Terms and Conditions Agreement, filling out your application form and uploading your non-confidential project plan.

Timeline

SGT
Enter
SGT
Submission deadline
SGT
Judging process begins
SGT
Finalist mentoring sessions begin
SGT
Finalists live presentations to Judges
SGT
Winner Announcement

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation – JLINX, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

 

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

Image paragraph
Image paragraph